ライフサイエンスコーパス: cyclo

1 ne, oxytetracycline, erythromycin, spinosad, cyclo-1,3,5,7-tetramethylene tetranitrate (HMX), and cyc

2 ,3,5-trimethylenetrinitramine (RDX), tetryl, cyclo-1,3,5,7-tetramethylenetetranitrate (HMX), hexameth

3 3,5,7-tetramethylene tetranitrate (HMX), and cyclo-1,3,5-trimethylene trinitramine (RDX)).

4 then 2:1 adducts between the high explosive cyclo-1,3,5-trimethylene-2,4,6-trinitramine (RDX) and ha

5 f the commonly used secondary explosive RDX (cyclo-1,3,5-trimethylene-2,4,6-trinitramine).

6 tetranitrate (PETN), trinitrotoluene (TNT), cyclo-1,3,5-trimethylenetrinitramine (RDX), tetryl, cycl

7 Reported here is a new hybrid macrocycle, cyclo[1]furan[1]pyridine[4]pyrrole (1), that bears analo

8 anolone, (3alpha,5alpha,20E)-3-hydroxy-13,24-cyclo-18-norcholan-20-ene-21-carbonitrile, eltanolone, 5

9 We generated cyclo[18]carbon (C(18)) using atom manipulation on bilay

10 Cyclo[18]carbon (C(18), a molecular carbon allotrope) ca

11 xide molecule, C(24)O(6) Characterization of cyclo[18]carbon by high-resolution atomic force microsco

12 ns including the stereoisomeric R and S 5',8-cyclo-2'-deoxyadenosine (cdA) and 5',8-cyclo-2'-deoxygua

13 8,5'-cyclo-2'-deoxyadenosine (cdA) and 8,5'-cyclo-2'-deoxygua

14 ry of DNA damage products including the 8,5'-cyclo-2'-deoxyadenosine (cdA) and 8,5'-cyclo-2'-deoxygua

15 rst evidence that both (5'R)- and (5'S)-5',8-cyclo-2'-deoxyadenosine (cdA) in a CAG repeat tract caus

16 -cyclo-2'-deoxyguanosine (cyclo-dG) and 8,5'-cyclo-2'-deoxyadenosine (cyclo-dA) in five different str

17 n human cells, the oxidative DNA lesion 8,5'-cyclo-2'-deoxyadenosine (CydA) induces prolonged stallin

18 n the significant accumulation of (5'R)-8,5'-cyclo-2'-deoxyadenosine (R-cdA) and (5'S)-8,5'-cyclo-2'-

19 clo-2'-deoxyadenosine (R-cdA) and (5'S)-8,5'-cyclo-2'-deoxyadenosine (S-cdA) in liver DNA of neil1(-/

20 ure 8-hydroxy-2'-deoxyguanosine, (5'-S)-8,5'-cyclo-2'-deoxyadenosine, (5'-R)-8,5'-cyclo-2'-deoxyguano

21 5',8-cyclo-2'-deoxyadenosine (cdA) and 5',8-cyclo-2'-deoxyguanosine (cdG) pairs that have been detec

22 8,5'-cyclo-2'-deoxyadenosine (cdA) and 8,5'-cyclo-2'-deoxyguanosine (cdG) tandem lesions.

23 esions including (5'S) diastereomers of 8,5'-cyclo-2'-deoxyguanosine (cyclo-dG) and 8,5'-cyclo-2'-deo

24 do-5-formamido-2-iminohydantoin (d2Ih), 5',8-cyclo-2'-deoxyguanosine (cyclo-dG), and the free base gu

25 8,5'-cyclo-2'-deoxyadenosine (cdA) and 8,5'-cyclo-2'-deoxyguanosine generated in DNA by both endogen

26 The 8,5'-cyclo-2'-deoxyguanosine lesion (cdG) has been recently r

27 S)-8,5'-cyclo-2'-deoxyadenosine, (5'-R)-8,5'-cyclo-2'-deoxyguanosine, and (5'-S)-8,5'-cyclo-2'-deoxyg

28 ,5'-cyclo-2'-deoxyguanosine, and (5'-S)-8,5'-cyclo-2'-deoxyguanosine.

29 5',8-cyclo-2'-deoxypurines (cdPus) are common forms of oxidiz

30 nt an oxidative deamination to produce 3,5'- cyclo-2'-deoxyxanthosine (19), whereas 17 was hydrolyzed

31 action with malonyl dichloride to afford two cyclo-[2]-malonate tethers that were separated by column

32 hat the flexible tetraimidazolium macrocycle cyclo[2](2,6-bis(1H-imidazol-1-yl)pyridine)[2](1,4-dimet

33 previously reported mixed heterocycle system cyclo[2]pyridine[4]pyrrole (2) and cyclo[6]pyrrole 3, an

34 nctional properties of 1 and the octapeptide cyclo(3-14)H-Cys-Phe-Phe-Trp(8)-Lys-Thr-Phe-Cys-OH (soma

35 logical properties of astressin B analogues {cyclo(30-33)[D-Phe(12),Nle(21,38),C(alpha)MeLeu(27,40),G

36 t, a CRF2 receptor antagonist (astressin-2B [cyclo(31-34) [d-Phe11,His12,C alphaMeLeu13,39, Nle17, Gl

37 A series of cyclo-3beta-(4-aminophenyl)-2beta-tropanemethanol analog

38 Cyclo-3beta-(4-aminophenyl)-2beta-tropanemethanol pimeli

39 Cyclo-3beta-(4-aminophenyl)-2beta-tropanemethanol sebaci

40 The congener TIP peptide AP318 [Cyclo(4-aminobutanoic acid-GQRETPEGAEAKPWYD)] activated

41 Several 6- and 7-monosubstituted N3,5'-cyclo-4-(beta-d-ribofuranosyl)-vic-triazolo[4,5-b]pyridi

42 , respectively) than the lead compound N3,5'-cyclo-4-(beta-D-ribofuranosyl)-vic-triazolo[4,5-b]pyridi

43 with alternate bridging constraints such as cyclo (6-11), cyclo (6-12), and cyclo (7-11).

44 e bridging constraints such as cyclo (6-11), cyclo (6-12), and cyclo (7-11).

45 The quinquedentate macrocyclic ligand cyclo-6,6'-[1,9-(2,5,8-trithianonane)]-2,2'-bipyridine (

46 The crystal structure of a homologous cyclo[6]aramide reveals a disk-shaped, near-planar molec

47 Additionally, cyclo[6]aramides show unusual mesophase transitions from

48 Cyclo[6]aramides, a type of macrocycle with a hydrogen-b

49 The various forms of cyclo[6]pyridine[6]pyrrole are characterized by distinct

50 A large porphyrin analogue, cyclo[6]pyridine[6]pyrrole, containing no meso bridging

51 le system cyclo[2]pyridine[4]pyrrole (2) and cyclo[6]pyrrole 3, an all-pyrrole 22 pi-electron aromati

52 It was also found that cyclo[6]pyrrole bound to d(T(2)AG(3))(4) better than oct

53 ctaethylporphyrin, a finding rationalized by cyclo[6]pyrrole having a 2+ charge, while octaethylporph

54 ints such as cyclo (6-11), cyclo (6-12), and cyclo (7-11).

55 recedented 3',8-cyclization of GTP into 3',8-cyclo-7,8-dihydro-GTP (3',8-cH(2)GTP) during the molybde

56 view was challenged by the isolation of 3',8-cyclo-7,8-dihydro-guanosine 5'-triphosphate (3',8-cH2GTP

57 e structure of this molecule to be (8S)-3',8-cyclo-7,8-dihydroguanosine 5'-triphosphate (3',8-cH2GTP)

58 system, consisting of an expanded porphyrin, cyclo[8]pyrrole (C8) and a pyrene carboxylate (Py) is ca

59 micros, which decays to the triplet state of cyclo[8]pyrrole, also an exceedingly long-lived species.

60 2-hydroxypropyl-beta-cyclodextrin (CYCLO), a modifier of cholesterol efflux from cellular m

61 ynthetase (PKS-NRPS) that makes and releases cyclo-acetoacetyl-L-tryptophan (cAATrp), the tetramic ac

62 peptide synthetase (PKS-NRPS) that generates cyclo-acetoacetyl-L-tryptophan (cAATrp).

63 These findings suggest that CYCLO acutely reverses the lysosomal transport defect se

64 enerated by copper-catalyzed [3 + 2] Huisgen cyclo-addition between an alkyne-functionalized C5-thymi

65 ro-2-nitrovinylbenzene, to trap the putative cyclo-addition intermediate, thereby demonstrating that

66 acyclic intermediate formed by a 1,3 dipolar cyclo-addition of prFMN with the alpha-beta double bond

67 MN can function as a dipole in a 1,3 dipolar cyclo-addition reaction as the initial step in a novel t

68 ol by attaching an azide fluorophore through cyclo-addition.

69 However, enzyme-catalyzed 1,3 dipolar cyclo-additions are unprecedented and other mechanisms a

70 e dose of 2-hydroxypropyl-beta-cyclodextrin (CYCLO) administered at 7 days of age immediately caused

71 The experimental spectrum for protonated cyclo AG compares very well with the theoretical spectra

72 rom the reaction of OH with a series of C10 (cyclo)alkanes, with 0-3 rings, in order to better unders

73 ylation of ketones to yield aryl benzyl and (cyclo)alkyl benzyl ketones with substitution patterns th

74 n emission tomography (PET) and [(64)Cu]DOTA-cyclo-(Arg-Gly-Asp-dPhe-Lys) {[(64)Cu]DOTA-c(RGDfK)} can

75 )](2), where E[c(RGDfk)](2) = glutamic acid-[cyclo(arginyl-glycyl-aspartic acid-D-phenylalanine-lysin

76 (4:4)-As4)] (3a) and [(Cp'''Fe)2(mu,eta(4:4)-cyclo-As4)] (3b).

77 he expected complex [(Cp(Bn)Fe)2(mu,eta(4:4)-cyclo-As4)](+).

78 y, cyclic peptides derived from MTII, Ac-Nle-cyclo(Asp-His6-D-Phe7-Arg8-Trp-Lys)-NH2 (a pan-agonist a

79 They are exemplified by peptide 29, Ac-Nle-cyclo(Asp-Oic6-D-4,4'-Bip7-Pip8-Trp-Lys)-NH2 (Oic=octahy

80 identical withMo(N[(i)Pr]Ar)(3) leads to the cyclo-AsP(2) complex (OC)(5)W(cyclo-AsP(2))Mo(N[(i)Pr]Ar

81 ) leads to the cyclo-AsP(2) complex (OC)(5)W(cyclo-AsP(2))Mo(N[(i)Pr]Ar)(3).

82 cyclo[D-Asp(7),Lys(10)]- and cyclo[Asp (6),Lys(10)]N/OFQ(1-13)NH2 exhibit high affini

83 d synthesis of aryl and heteroaryl-annulated cyclo[b]carbazoles has been developed via SnCl4-mediated

84 The Cope rearrangement of cyclo-biphenalenyl 9 is studied by exploring its potenti

85 idence for lysosomal enhancing properties of CYCLO, but caution that prolonged interference with cell

86 based upon cationic [Rh(PCy(3))(2)](+) (Cy = cyclo-C(6)H(11)).

87 (2)(Ar)(HX) (X = NHAlk; Alk = n-Bu, PhCH(2), cyclo-C(6)H(11), t-Bu, cyclopropylmethyl) bearing a bulk

88 r is aromatic, and in partially hydrogenated cyclo-C18 derivatives with both radial and tangential pi

89 3b, C6H4-4-NEt23d; CR2 = adamantylidene 3c, cyclo-C3Ph23e).

90 C6H3N=CMe)2C5H3N; R = Et, (n)Bu, (i)Bu, CH2 (cyclo)C5H 9; 1-R), were synthesized either by direct alk

91 Reductive cyclo-carbopalladation of suitable Ugi-4CR substrates as

92 AP301 [Cyclo(CGQRETPEGAEAKPWYC)], a cyclic peptide comprising t

93 One of these peptides, cyclo-[(CH(2))(3)CO-Gly(1)-His(2)-D-Phe(3)-Arg(4)-D-Trp(

94 Here we report cyclo-CLLFVY, identified from a library of 3.2 million c

95 observed to react with 3-Mo to generate the cyclo-CP2 complex (AdCP2)Mo(N[(i)Pr]Ar)3.

96 f N-methylated analogues of the stem peptide cyclo(d-Ala-Ala5 ); 2) selection of cyclic peptides with

97 en positions 5 and 8 yielded [N-benzylTyr(1),cyclo(d-Asp(5),Dap(8))]Dyn A-(1-11)NH(2) (zyklophin, 13)

98 (Dyn) A analogue zyklophin ([N-benzyl-Tyr(1)-cyclo(d-Asp(5),Dap(8))]dynorphin A(1-11)NH2) is a kappa

99 ane affinity of the decapeptide Gramicidin S cyclo(d-Phe-Pro-Val-Orn-Leu-)2 (GS).

100 s) for the important model cyclopentapeptide cyclo(D-Pro1-Ala2-Ala3-Ala4-Ala5) were performed in expl

101 template structures based on a library of 54 cyclo(-D-Ala-Ala(5)-) peptides with different N-methylat

102 Cyclo-(d-Pro-l-Pro-d-Pro-l-Pro) has been studied with de

103 cyclo[D-Asp(7),Lys(10)]- and cyclo[Asp (6),Lys(10)]N/OFQ

104 ical constraints with penicillamines, 2 (Tyr-cyclo[d-Pen-Gly-Phe-Pen]-Pro-Leu-Trp-NH-[3',5'-(CF(3))(2

105 (cyclo-dG) and 8,5'-cyclo-2'-deoxyadenosine (cyclo-dA) in five different strains of Escherichia coli

106 roups, prior to the intramolecular oxidative cyclo-dehydrogenation.

107 Cryptophycins, naturally occurring cytotoxic cyclo-depsipeptides, have been modified by total synthes

108 cells with LR-disrupting agents methyl beta-cyclo dextrin (MbetaCD) or nystatin significantly inhibi

109 we also isolated significant amounts of 3,5'-cyclo-dG (16) and 2,5'-cyclo-dT (17), respectively.

110 astereomers of 8,5'-cyclo-2'-deoxyguanosine (cyclo-dG) and 8,5'-cyclo-2'-deoxyadenosine (cyclo-dA) in

111 antoin (d2Ih), 5',8-cyclo-2'-deoxyguanosine (cyclo-dG), and the free base guanine (Gua).

112 ared by the palladium-catalyzed ring-opening cyclo-dimerization of the three-membered heterocycle Re(

113 ed conversion of 2-C-methyl-D-erythritol-2,4-cyclo-diphosphate into (E)-1-hydroxy-2-methylbut-2-enyl-

114 the substrate, 2-C-methyl-D-erythritol-2, 4-cyclo-diphosphate.

115 of Me2PCl and TMSOTf to form the unexpected cyclo-diphosphino-1,2-diphosphonium salt [(Me2P)2(PtBu)2

116 The cyclo-diphosphinophosphonium salt [(PtBu)3Me][OTf] (2) h

117 cyclo[DKP-f3-RGD]-PTX 11 displayed sufficient stability

118 sized with the aim of using the tumor-homing cyclo[DKP-RGD] peptidomimetics for site-directed deliver

119 orms the biosynthetic step that provides the cyclo-DOPA moiety of all red betacyanins.

120 talamic acid condenses with imino compounds (cyclo-DOPA or its glucosyl derivatives), or amines and/o

121 A formation and its subsequent conversion to cyclo-DOPA, CYP76AD6 uniquely exhibits only tyrosine hyd

122 me P450 gene that catalyzes the formation of cyclo-DOPA.

123 Mice injected with Cyclo/Dox at ZT2 lost more body mass than mice injected

124 Cyclo/Dox injected at ZT2 increased the expression of se

125 within the liver responsible for converting Cyclo/Dox into their toxic metabolites increased among m

126 Mice were injected intravenously with Cyclo/Dox or the vehicle two hours after lights on (zeit

127 inistering cyclophosphamide and doxorubicin (Cyclo/Dox), a common treatment for breast cancer, to fem

128 icant amounts of 3,5'-cyclo-dG (16) and 2,5'-cyclo-dT (17), respectively.

129 Here, we investigated CYCLO effects on autophagy in wild-type mice and TgCRND8

130 f the alphavbeta6 integrin-selective peptide cyclo(FRGDLAFp(NMe)K) via click chemistry.

131 f the alphavbeta6 integrin-selective peptide cyclo(FRGDLAFp(NMe)K) via click chemistry.

132 glaucoma or OHT that underwent MPCPC (Iridex Cyclo G6 Glaucoma Laser System, Mountain View, CA) betwe

133 d cyclic peptide with 6 amino acid residues, cyclo(Gln-Trp-Phe-Gly-Leu-Met), is confirmed not to adop

134 dimethyl-6-t-butyl-dimethyl-silyoxy-methyl-1-cyclo-hexanone to give a vinyl cyclohexanol derivative a

135 )-3,4-dichloro-N-methyl-N-[2-1-pyrrolidinyl)-cyclo-hexyl] benzeneacetamide (U50488) into the LC did n

136 (10)-methylenetetrahydrofolate dehydrogenase/cyclo hydrolase (FolD) is essential for growth in Trypan

137 Second, CYCLO impeded autophagosome-lysosome fusion as evidenced

138 xaline, questiomycin A, cyclo (l-Pro-l-Val), cyclo (l-Pro-l-Tyr), bikaverin, kojic acid and 3-nitropr

139 les from year 2012, oxaline, questiomycin A, cyclo (l-Pro-l-Val), cyclo (l-Pro-l-Tyr), bikaverin, koj

140 e identified two volatile cyclic dipeptides, cyclo(L-Leu-L-Pro) and cyclo(L-Pro-L-Pro), from the comp

141 hemical blend, compared to the controls, the cyclo(L-Leu-L-Pro) blend, or a combined blend with both

142 yclo(L-Pro-L-Pro) and a modulating effect of cyclo(L-Leu-L-Pro) that may depend on the relative conce

143 ts suggest a potential semiochemical role of cyclo(L-Pro-L-Pro) and a modulating effect of cyclo(L-Le

144 ickings) when presented with the synthesised cyclo(L-Pro-L-Pro) chemical blend, compared to the contr

145 le cyclic dipeptides, cyclo(L-Leu-L-Pro) and cyclo(L-Pro-L-Pro), from the complex mixture of a chemic

146 itro show that it can use the cyclodipeptide cyclo(l-Tyr-l-Tyr) (cYY) as a substrate.

147 The introduction of iodine substituents onto cyclo(l-tyrosyl-l-tyrosine) results in sub-muM binding a

148 A series of analogues of cyclo(l-tyrosyl-l-tyrosine), the substrate of the Mycoba

149 jects with severe periodontitis (P2 and P3), cyclo (-leu-pro) and cyclo (-phe-pro) were significantly

150 strongly associated with 2 novel metabolites-cyclo (-leu-pro) and cyclo (-phe-pro)-at 21 d of biofilm

151 the presence of the pulcherrimin precursors cyclo(Leu-Leu) and pulcherriminic acid and identified ne

152 e pigment pulcherrimin, from cyclodileucine (cyclo(Leu-Leu)) as a precursor, and exhibits strong anti

153 (MTHFS; also called 5-formyltetrahydrofolate cyclo-ligase; EC 6.3.3.2) activity responsible for the o

154 Novel hybrid cyclo[m]pyridine[n]pyrroles have been synthesized using

155 tedly generated the cyclic phosphonium salt [cyclo-{(Mes)P}(2) P(Mes)(2) ][BAr(F) (4) ].CyMe through

156 ing only 1,1'-disubstituted ferrocene units (cyclo[n], n = 5-7, 9).

157 from rings of two-coordinate atoms, known as cyclo[n]carbons, have fascinated chemists for many years

158 lision cross section of each d(T(2)AG(3))(4)/cyclo[n]pyrrole complex.

159 tiparallel G-quadruplex arrangement and each cyclo[n]pyrrole externally stacked below the G-quartets

160 Nano-ESI-MS indicated that the smaller the cyclo[n]pyrrole, the more strongly it binds to the telom

161 a similar function, a series of diprotonated cyclo[n]pyrroles (where n = 6, 7, and 8) was each added

162 As a first step toward testing whether cyclo[n]pyrroles display a similar function, a series of

163 ) and (2) the overall size and charge of the cyclo[n]pyrroles play important roles in defining the bi

164 Diprotonated cyclo[n]pyrroles represent a set of expanded porphyrin a

165 When the cyclo[n]pyrroles were intercalated or nonspecifically bo

166 dominant binding mode for the interaction of cyclo[n]pyrroles with d(T(2)AG(3))(4) and (2) the overal

167 expanded compounds that are examined include cyclo[n]pyrroles, [22]pentaphyrins(1.1.1.1.1), sapphyrin

168 dy using the IgG binding cyclic depsipeptide cyclo[(Nalpha-Ac)-S(A)-RWHYFK-Lact-E] is presented to de

169 (CO)4] (4a) but instead lead to (bisNHC)Al(2-cyclo-OC4H7)[Fe(CO)4] (4) and (bisNHC)Al(2-cyclo-OC5H9)[

170 2-cyclo-OC4H7)[Fe(CO)4] (4) and (bisNHC)Al(2-cyclo-OC5H9)[Fe(CO)4] (5), respectively.

171 two surfaces in the 24-dimensional space of cyclo-octane conformations and by locating all of the se

172 clopentadienyl, arene, cycloheptatrienyl and cyclo-octatetraenide complexes, cyclobutadienyl derivati

173 with uranium complexes of larger arenes and cyclo-octatetraenide, where delta-bonding dominates.

174 azide was then selectively derivatized with cyclo-octyne conjugates to various probes.

175 on thin-film gold electrodes deposited onto Cyclo Olefin Polymer (COP) substrates was fabricated for

176 d to an AS18 latex-coated surface-sulfonated cyclo-olefin polymer (COP) capillary column with an inne

177 Thermoplastics such as polystyrene (PS) and cyclo-olefin polymer (COP) have become common materials

178 ice was based on a disposable and single-use cyclo-olefin polymer (COP) microfluidic chip interfaced

179 three different materials (polystyrene (PS), cyclo-olefin polymer (COP), and PDMS).

180 the experiments establish that a step-growth cyclo-oligomerization process operates during CB[n] form

181 We identified two major actions of CYCLO on autophagy underlying amelioration of lysosomal

182 Should selective cyclo-oxygenase (COX) 2 inhibitors be used?

183 and whether its effects are mediated through cyclo-oxygenase (COX) and prostaglandins (PG).

184 ed vasodilatation with nitric oxide (NO) and cyclo-oxygenase (COX) signalling pathways, microdialysis

185 prostacyclin (PGI2) derived from adenoviral cyclo-oxygenase (COX)-1/prostacyclin synthase (PGIS) (Ad

186 Cyclo-oxygenase (COX)-2 selective inhibitors decrease up

187 Upper gastrointestinal safety of cyclo-oxygenase (COX)-2 selective inhibitors versus trad

188 Increased generation of cyclo-oxygenase (COX-1 and COX-2)-derived vasoconstricto

189 a-2 agonists, beta-blockers,corticosteroids, cyclo-oxygenase 2 inhibitors, and regional anesthetic bl

190 Current exposure to cyclo-oxygenase 2 selective and non-selective NSAIDs was

191 including overexpression of IL-6, IL-1beta, cyclo-oxygenase 2, M-CSF, and IDO.

192 nducible NO synthase, arginase-1, TNF-alpha, cyclo-oxygenase 2, vascular endothelial growth factor [V

193 , alternatively, the restoration of PTHrP or cyclo-oxygenase activity by the administration of PTH an

194 t acetaminophen is an effective inhibitor of cyclo-oxygenase activity in intact cells.

195 ise mechanism of action for acetaminophen on cyclo-oxygenase activity is debated.

196 ophen has no affinity for the active site of cyclo-oxygenase but instead blocks activity by reducing

197 shes bombesin-induced gastroprotection while cyclo-oxygenase inhibition partially reverses this effec

198 d reduced ET-induced vascular leakage with a cyclo-oxygenase inhibitor (indomethacin), agents that in

199 yet, undeveloped therapeutic window for the "cyclo-oxygenase inhibitor".

200 ed in the presence of high concentrations of cyclo-oxygenase inhibitor, aspirin.

201 administration of indomethacin or celecoxib (cyclo-oxygenase inhibitors), pyrilamine, aprepitant (a n

202 and substrate supply, and not the isoform of cyclo-oxygenase present, dictate the effects of NSAIDs o

203 Acetaminophen works by lowering cyclo-oxygenase products preferentially in the central n

204 vity by reducing the active oxidized form of cyclo-oxygenase to an inactive form.

205 e caused by the previous suggested effect on cyclo-oxygenase, as inhibition also was observed in the

206 , unco-ordinated-5H3 (unc5H3), doublecortin, cyclo-oxygenase, sonic hedgehog and Disrupted in schizop

207 man vessels and endothelial cells containing cyclo-oxygenase-1 (COX-1) without any detectable COX-2,

208 hacin or diclofenac, which also inhibit both cyclo-oxygenase-1 and cyclo-oxygenase-2, were unaffected

209 hrombogenicity, whereas markers sensitive to cyclo-oxygenase-1 blockade are increased in the absence

210 Markers sensitive to cyclo-oxygenase-1 blockade, including platelet reactivit

211 2 selective inhibitor rofecoxib or the mixed cyclo-oxygenase-1/cyclo-oxygenase-2 inhibitors ibuprofen

212 ripts of a limited number of genes including cyclo-oxygenase-2 (COX-2) and major histocompatibility c

213 ates parathyroid-related peptide (PTHrP) and cyclo-oxygenase-2 (COX-2) as possible factors underlying

214 ophosphatidic acid (LPA) lead to synergistic cyclo-oxygenase-2 (COX-2) expression, an enzyme strongly

215 -2), matrix metalloproteinase-9 (MMP-9), and cyclo-oxygenase-2 (COX-2) in the mammary gland.

216 Cyclo-oxygenase-2 (COX-2) selective inhibitors have been

217 of interleukin-8 (IL-8), IL-6, IL-1beta, and cyclo-oxygenase-2 (COX-2) were greatest in differentiate

218 Cyclo-oxygenase-2 (COX-2), an inducible enzyme important

219 SAIDs), particularly selective inhibitors of cyclo-oxygenase-2 (COX-2), is associated with an increas

220 expression of the pro-inflammatory mediator cyclo-oxygenase-2 (COX-2), providing a mechanism whereby

221 Here, we have used an in vitro model of cyclo-oxygenase-2 activity (A549 cells stimulated with I

222 uated by inhibiting the prostanoid mediators cyclo-oxygenase-2 and 5-lipoxygenase and CC chemokine re

223 t of titres of lentiviral vectors expressing Cyclo-oxygenase-2 by 600-fold, and adenoviral vectors ex

224 Selective inhibition of cyclo-oxygenase-2 has been associated with an increased

225 over nonsteroidal anti-inflammatory drug and cyclo-oxygenase-2 inhibitor safety continues.

226 sessed the effect of 3-year treatment with a cyclo-oxygenase-2 inhibitor, rofecoxib (25 mg), on recur

227 tor rofecoxib or the mixed cyclo-oxygenase-1/cyclo-oxygenase-2 inhibitors ibuprofen and naproxen were

228 ear has led to a reassessment of the role of cyclo-oxygenase-2 inhibitors in osteoarthritis therapy a

229 c pain is typically treated with opioids and cyclo-oxygenase-2 inhibitors with well known side effect

230 of nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors.

231 Similarly the inhibitory effects of the cyclo-oxygenase-2 selective inhibitor rofecoxib or the m

232 some NSAIDs, including the newly introduced cyclo-oxygenase-2 selective inhibitor rofecoxib, owe par

233 Cyclo-oxygenase-2 selective inhibitors and non-selective

234 s of nonsteroidal anti-inflammatory drug and cyclo-oxygenase-2 therapy for individuals is covered.

235 Cyclo-oxygenase-2(-/-) mice had increased plasma levels

236 okeratin, high-molecular-weight cytokeratin, cyclo-oxygenase-2, EMA, HER2, matrix metalloproteinases

237 hich also inhibit both cyclo-oxygenase-1 and cyclo-oxygenase-2, were unaffected by t-butylOOH.

238 ious impact that select therapies (including cyclo-oxygenase-2-specific inhibitors) may have in terms

239 In addition, nitric oxide and cyclo-oxygenase-derived byproducts are required for full

240 ory actions to effects on oxidation state of cyclo-oxygenase.

241 a 1-week high-salt (HS) diet on the role of cyclo-oxygenases (COX-1 and COX-2) and the vasoconstrict

242 ng terminals, but resistant to inhibition of cyclo-oxygenases.

243 Cyclo-P(3) complexes can be obtained when ancillary liga

244 be viewed as the simple coordination of the [cyclo-P(4) ](2-) dianion to a neutral metal fragment.

245 Treatment of the neutral, molybdenum cyclo-P(4) complexes Mo(eta(4) -P(4) )I(2) (CO)(CNAr(Dip

246 s species (that is, cyclo-P(n) ), the planar cyclo-P(4) group is unique in its requirement of two add

247 tetrahedral P(4) molecule from a mononuclear cyclo-P(4) molybdenum complex.

248 nd insertion reactions of silylenes into the cyclo-P(5) ring of [Cp*Fe(eta(5)-P(5))] are reported.

249 The insertion of [LSi-SiL] into the cyclo-P(5) ring of [Cp*Fe(eta(5)-P(5))] resulted in [{et

250 p*}], in which the silicon atom binds to the cyclo-P(5) ring, was synthesized as a model compound for

251 in [{eta(4)-P(5)(SiL)(2)}FeCp*] featuring a cyclo-P(5)(SiL)(2) ring, which corresponds to the larges

252 her cyclic poly-phosphorus species (that is, cyclo-P(n) ), the planar cyclo-P(4) group is unique in i

253 ple bond]Nb(N[Np]Ar)3](-), 3-Nb, to give the cyclo-P3 complexes (P3)M(N[(i)Pr]Ar)3 and [(P3)Nb(N[Np]A

254 butylimido complexes to produce the bridging cyclo-P4 phosphide species {[(BDI)(N(t)Bu)M]2(mu-eta(3):

255 All prior examples of cyclo-P5 are stabilized by d-block metals, so 2 shows th

256 from uranium to the cyclo-P5 unit to give a cyclo-P5 charge state that approximates to a dianionic f

257 rger size and superior acceptor character of cyclo-P5 compared to cyclopentadienyl, the strongly redu

258 the unprecedented actinide inverted sandwich cyclo-P5 complex [{U(Tren(TIPS))}2(mu-eta(5):eta(5)-cycl

259 tabilized by d-block metals, so 2 shows that cyclo-P5 does not require d-block ions to be prepared.

260 Although cyclo-P5 is isolobal to cyclopentadienyl, which usually

261 ls three different coordination modes of the cyclo-P5 ligand including a novel pi-coordination.

262 ent with charge transfer from uranium to the cyclo-P5 unit to give a cyclo-P5 charge state that appro

263 5 complex [{U(Tren(TIPS))}2(mu-eta(5):eta(5)-cyclo-P5)] (2).

264 thiaspirane nuphar alkaloid from 3-methyl-2-cyclo-pentenone is reported.

265 iodontitis (P2 and P3), cyclo (-leu-pro) and cyclo (-phe-pro) were significantly associated with incr

266 ith 2 novel metabolites-cyclo (-leu-pro) and cyclo (-phe-pro)-at 21 d of biofilm overgrowth (P = 0.02

267 The cyclo(Phe-Pro) inhibition of CT and TCP production corre

268 In this work, we present evidence that cyclo(Phe-Pro) inhibits the production of the virulence

269 Cyclo(Phe-Pro) is a cyclic dipeptide produced by multipl

270 piro-ionenes are successfully synthesized in cyclo-polycondensations of tetrakis(bromomethyl)benzene

271 ) a one-pot reaction of phosphonium dimers ([cyclo-(PR2CH2CH(OH)(-))2][Br]2), KOtBu, FeBr2, and Ph2PC

272 the orally bioavailable somatostatin analog cyclo(-Pro-Phe-NMe-D-Trp-NMe-Lys-Thr-NMe-Phe-), and the

273 ced the percentage of lysophospholipids, and cyclo-propane bonds containing acyl chains.

274 lo[R-G-D-f-N(Me)V] 1, and its parent peptide cyclo(R-G-D-f-V) 2, potent antagonists of the alphavbeta

275 ormed on the cyclic RGD-peptide Cilengitide, cyclo[R-G-D-f-N(Me)V] 1, and its parent peptide cyclo(R-

276 By 49 days of age, this single injection of CYCLO resulted in a reduction in whole-body C burden of

277 der of potency of GRGDNP > GRGDSP > GRGDTP = cyclo-RGD.

278 ptor-specific binding and cellular uptake of cyclo(RGDfC)-modified quantum dots via the alphavbeta3 i

279 knottin-RGD peptide instead of biotinylated cyclo[RGDfK] (as reported by Piras et al.), as integrin-

280 d alpha5beta1, while binding of biotinylated cyclo[RGDfK] was very weak and only detectable for alpha

281 ed peptides, that is: (i) linear GRGDS, (ii) cyclo[RGDfK], and (iii) the knottin-RGD itself for bindi

282 halasin D (to block actin polymerization) or cyclo(RGDfV) (to block vitronectin receptors) significan

283 Blocking studies with cyclo[RGDfV] inhibited the in vivo uptake of Cyp-GRD, su

284 The synthetic cyclic hexapeptide cWFW (cyclo(RRRWFW)) has a rapid bactericidal activity against

285 Dipeptide cyclo[(S)-His-(S)-Phe] 1, first applied by Inoue et al.

286 The tris-cyclo-salophen(12-) ligand is perfectly suited for bindi

287 amide, hexaphenolate macrocyclic ligand tris-cyclo-salophen(12-).

288 The hexanuclear [Na(12)Fe(6)(tris-cyclo-salophen)(2)(THF)(14)], 1-THF, and the trinuclear

289 , 1-THF, and the trinuclear [Na(6)Fe(3)(tris-cyclo-salophen)(py)(9)], 1-py, Fe(II) clusters can be ea

290 Evolidine (cyclo-SFLPVNL) has subsequently been all but forgotten i

291 and 0.075nmol)], and specific MC4-R agonist (cyclo [ss-Ala-His-D-Phe-Arg-Trp-Glu]-NH2; 0.024nmol) bot

292 First, CYCLO stimulated lysosomal proteolytic activity by incre

293 ture of a unique series of dinuclear group 5 cyclo-tetraphosphide inverted sandwich complexes.

294 by comparative studies of the corresponding cyclo-tetraphosphorus cation in [(PtBu)4Me][OTf] (10), w

295 ay intracerebroventricular administration of CYCLO to 8-month-old TgCRND8 mice that exhibit moderatel

296 e synthesis are a microwave-mediated [2+2+2] cyclo-trimerization reaction to construct the central be

297 a[NV(N[(t)Bu]Ar)3] (Na[4]) to yield trimeric cyclo-triphosphane [PNV(N[(t)Bu]Ar)3]3 (3) with a core c

298 One peptide, cyclo-(VVGGVG) or P7, was predicted to be unusually well

299 with a less well-structured control peptide, cyclo-(VVGVGG) or P6, and characterized their global str

300 ualed 79 mg x d(-1) x kg(-1), treatment with CYCLO within 24 h increased C movement out of the E/L co